FDA Grants Breakthrough Therapy Designation to First Oral Drug for Suicidal Bipolar Depression

NeuroRx, announced on 11/13/18 that it has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for development of NRX-101.